Literature DB >> 35464264

Drivers and breaks in the cholangiocarcinoma immune microenvironment.

Caitlin B Conboy1, Sumera I Ilyas2, Gregory J Gores2.   

Abstract

Entities:  

Year:  2022        PMID： 35464264      PMCID： PMC9023837          DOI： 10.21037/hbsn-21-572

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   8.265


× No keyword cloud information.
  9 in total

1.  Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.

Authors:  Sarina A Piha-Paul; Do-Youn Oh; Makoto Ueno; David Malka; Hyun Cheol Chung; Adnan Nagrial; Robin K Kelley; Willeke Ros; Antoine Italiano; Kazuhiko Nakagawa; Hope S Rugo; Filippo de Braud; Andrea Iolanda Varga; Aaron Hansen; Hui Wang; Suba Krishnan; Kevin G Norwood; Toshihiko Doi
Journal:  Int J Cancer       Date:  2020-05-02       Impact factor: 7.396

2.  A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.

Authors:  Richard D Kim; Vincent Chung; Olatunji B Alese; Bassell F El-Rayes; Daneng Li; Taymeyah E Al-Toubah; Michael J Schell; Jun-Min Zhou; Amit Mahipal; Baek Hui Kim; Dae Won Kim
Journal:  JAMA Oncol       Date:  2020-06-01       Impact factor: 31.777

3.  Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.

Authors:  Emilien Loeuillard; Jingchun Yang; EeeLN Buckarma; Juan Wang; Yuanhang Liu; Caitlin Conboy; Kevin D Pavelko; Ying Li; Daniel O'Brien; Chen Wang; Rondell P Graham; Rory L Smoot; Haidong Dong; Sumera Ilyas
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

4.  Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.

Authors:  Oliver Klein; Damien Kee; Adnan Nagrial; Ben Markman; Craig Underhill; Michael Michael; Louise Jackett; Caroline Lum; Andreas Behren; Jodie Palmer; Niall C Tebbutt; Matteo S Carlino; Jonathan Cebon
Journal:  JAMA Oncol       Date:  2020-09-01       Impact factor: 31.777

Review 5.  Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.

Authors:  Jérôme Galon; Daniela Bruni
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

6.  The immunogenomic landscape of resected intrahepatic cholangiocarcinoma.

Authors:  Fernando Carapeto; Behnaz Bozorgui; Rachna T Shroff; Sharmeen Chagani; Luisa Solis Soto; Wai Chin Foo; Ignacio Wistuba; Funda Meric-Bernstam; Ahmed Shalaby; Milind Javle; Anil Korkut; Lawrence N Kwong
Journal:  Hepatology       Date:  2021-12-06       Impact factor: 17.425

7.  ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance.

Authors:  Jacob J Orme; Khalid A Jazieh; Tiancheng Xie; Susan Harrington; Xin Liu; Matthew Ball; Benjamin Madden; M Cristine Charlesworth; Tariq U Azam; Fabrice Lucien; Bharath Wootla; Yanli Li; Jose Caetano Villasboas; Aaron S Mansfield; Roxana S Dronca; Haidong Dong
Journal:  Oncoimmunology       Date:  2020-04-14       Impact factor: 8.110

Review 8.  Immunobiology of cholangiocarcinoma.

Authors:  Emilien Loeuillard; Caitlin B Conboy; Gregory J Gores; Sumera Rizvi
Journal:  JHEP Rep       Date:  2019-07-10

9.  Myeloid Cell Infiltration Correlates With Prognosis in Cholangiocarcinoma and Varies Based on Tumor Location.

Authors:  Paul R Kunk; Sean C Dougherty; Kevin Lynch; Rachel Whitehair; Max Meneveau; Joseph M Obeid; Kevin Winters; Jennifer Y Ju; Edward B Stelow; Todd W Bauer; Craig L Slingluff; Osama E Rahma
Journal:  J Immunother       Date:  2021-09-01       Impact factor: 4.912
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.